VSTM Quote, Financials, Valuation and Earnings

Anavex Life Sciences Corp. has a net margin of -876.34% compared to Verastem, Inc.'s net margin of --. Verastem, Inc.'s return on equity of -1773.4% beat Anavex Life Sciences Corp.'s return on equity of -38.18%.

Verastem, Inc. has a consensus price target of $16.63, signalling upside risk potential of 191.16%. On the other hand Anavex Life Sciences Corp. has an analysts' consensus of $22.00 which suggests that it could grow by 444.56%. Given that Anavex Life Sciences Corp. has higher upside potential than Verastem, Inc., analysts believe Anavex Life Sciences Corp. is more attractive than Verastem, Inc..

Verastem, Inc. has a beta of 0.414, which suggesting that the stock is 58.56% less volatile than S&P 500. In comparison Anavex Life Sciences Corp. has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.178%.

Verastem, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Anavex Life Sciences Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem, Inc. pays -- of its earnings as a dividend. Anavex Life Sciences Corp. pays out -- of its earnings as a dividend.

Verastem, Inc. quarterly revenues are $11.2M, which are larger than Anavex Life Sciences Corp. quarterly revenues of --. Verastem, Inc.'s net income of -$98.5M is lower than Anavex Life Sciences Corp.'s net income of -$5.7M. Notably, Verastem, Inc.'s price-to-earnings ratio is -- while Anavex Life Sciences Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem, Inc. is 26.68x versus -- for Anavex Life Sciences Corp.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -876.34% compared to Verastem, Inc.'s net margin of 49.9%. Verastem, Inc.'s return on equity of -1773.4% beat CorMedix, Inc.'s return on equity of 95.25%.

Verastem, Inc. has a consensus price target of $16.63, signalling upside risk potential of 191.16%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 107.21%. Given that Verastem, Inc. has higher upside potential than CorMedix, Inc., analysts believe Verastem, Inc. is more attractive than CorMedix, Inc..

Verastem, Inc. has a beta of 0.414, which suggesting that the stock is 58.56% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.

Verastem, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Verastem, Inc. quarterly revenues are $11.2M, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Verastem, Inc.'s net income of -$98.5M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Verastem, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.49x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem, Inc. is 26.68x versus 2.41x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -876.34% compared to Verastem, Inc.'s net margin of -1144.46%. Verastem, Inc.'s return on equity of -1773.4% beat Ocugen, Inc.'s return on equity of -345.08%.

Verastem, Inc. has a consensus price target of $16.63, signalling upside risk potential of 191.16%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 508.11%. Given that Ocugen, Inc. has higher upside potential than Verastem, Inc., analysts believe Ocugen, Inc. is more attractive than Verastem, Inc..

Verastem, Inc. has a beta of 0.414, which suggesting that the stock is 58.56% less volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 3.493, suggesting its more volatile than the S&P 500 by 249.3%.

Verastem, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Verastem, Inc. quarterly revenues are $11.2M, which are larger than Ocugen, Inc. quarterly revenues of $1.8M. Verastem, Inc.'s net income of -$98.5M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Verastem, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem, Inc. is 26.68x versus 81.23x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Zevra Therapeutics, Inc. has a net margin of -876.34% compared to Verastem, Inc.'s net margin of -2.09%. Verastem, Inc.'s return on equity of -1773.4% beat Zevra Therapeutics, Inc.'s return on equity of 44.06%.

Verastem, Inc. has a consensus price target of $16.63, signalling upside risk potential of 191.16%. On the other hand Zevra Therapeutics, Inc. has an analysts' consensus of $22.54 which suggests that it could grow by 160.62%. Given that Verastem, Inc. has higher upside potential than Zevra Therapeutics, Inc., analysts believe Verastem, Inc. is more attractive than Zevra Therapeutics, Inc..

Verastem, Inc. has a beta of 0.414, which suggesting that the stock is 58.56% less volatile than S&P 500. In comparison Zevra Therapeutics, Inc. has a beta of 0.989, suggesting its less volatile than the S&P 500 by 1.074%.

Verastem, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zevra Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Verastem, Inc. pays -- of its earnings as a dividend. Zevra Therapeutics, Inc. pays out -- of its earnings as a dividend.

Verastem, Inc. quarterly revenues are $11.2M, which are smaller than Zevra Therapeutics, Inc. quarterly revenues of $26.1M. Verastem, Inc.'s net income of -$98.5M is lower than Zevra Therapeutics, Inc.'s net income of -$544K. Notably, Verastem, Inc.'s price-to-earnings ratio is -- while Zevra Therapeutics, Inc.'s PE ratio is 13.71x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Verastem, Inc. is 26.68x versus 5.60x for Zevra Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.